Send to

Choose Destination

See 1 citation found by title matching your search:

Oncotarget. 2017 Jun 27;8(26):42621-42637. doi: 10.18632/oncotarget.16730.

EGFR-induced phosphorylation of typephosphatidylinositol phosphate kinase promotes pancreatic cancer progression.

Author information

Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester MN, USA.
Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Shanghai East Hospital, Tongji University, Shanghai, China.


Pancreatic cancer is one of the deadliest malignancies and effective treatment has always been lacking. In current study, we investigated how the typephosphatidylinositol phosphate kinase (PIPKIγ) participates in the progression of pancreatic ductal adenocarcinoma (PDAC) for novel therapeutic potentials against this lethal disease. We found that PIPKIγ is up-regulated in all tested PDAC cell lines. The growth factor (including EGFR)-induced tyrosine phosphorylation of PIPKIγ is significantly elevated in in situ and metastatic PDAC tissues. Loss of PIPKIγ inhibits the aggressiveness of PDAC cells by restraining the activities of AKT and STAT3, as well as MT1-MMP expression. Therefore when planted into the pancreas of nude mice, PIPKIγ-depleted PDAC cells exhibits substantially repressed tumor growth and metastasis comparing to control PDAC cells. Results from further studies showed that the phosphorylation-deficient PIPKIγ mutant, unlike its wild-type counterpart, cannot rescue PDAC progression inhibited by PIPKIγ depletion. These findings indicate that PIPKIγ, functioning downstream of EGFR signaling, is critical to the progression of PDAC, and suggest that PIPKIγ is potentially a valuable therapeutic target for PDAC treatment.


EGFR; metastasis; pancreatic cancer; typephosphatidylinositol phosphate kinase; tyrosine phosphorylation

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center